Latest news with #CDMO
Economic Times
11 hours ago
- Business
- Economic Times
Influx Healthtech IPO subscribed over 41 times on Day 3; GMP signals strong listing
Influx Healthtech IPO GMP Live Events Business Overview and Fund Utilisation (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The Rs 55.63 crore initial public offering (IPO) of Influx Healthtech was subscribed 41.07 times by 11:26 a.m. on the final day of bidding, Friday, driven by strong interest from retail and non-institutional retail investor portion was subscribed 53.88 times, while the non-institutional investor (NII) segment saw 63.64 times subscription. The qualified institutional buyer (QIB) portion was subscribed 1.71 the grey market, Influx Healthtech shares were commanding a premium of Rs 37–38, indicating an estimated listing price of around Rs 134. This reflects a 39% gain over the issue's upper price band of Rs 96 per IPO opened on June 17 and closes today. It is priced in the range of Rs 91–96 per share, with a minimum lot size of 1,200 Influx Healthtech is a contract development and manufacturing organisation (CDMO) that offers third-party manufacturing and product development services across nutraceuticals, cosmetics, ayurvedic products, and veterinary feed manufacturing operations are based in Thane, where it produces a wide range of products including tablets, gummies, jellies, skincare solutions, and ayurvedic the Rs 55.63 crore raised, Rs 45.07 crore is through a fresh issue and Rs 10.56 crore via offer-for-sale. The company plans to utilise Rs 34.19 crore for establishing two new manufacturing facilities focused on nutraceutical and veterinary products, along with investments in machinery and general corporate FY25, Influx Healthtech reported revenue of Rs 104.99 crore and a net profit of Rs 13.37 shares are proposed to be listed on the NSE SME platform, with a tentative listing date of June 25.: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
11 hours ago
- Business
- Time of India
Influx Healthtech IPO subscribed over 41 times on Day 3; GMP signals strong listing
Influx Healthtech's IPO witnessed an overwhelming response, being oversubscribed 41.07 times, driven by strong retail and NII participation. The IPO, priced at Rs 91-96, saw grey market premiums suggesting a 39% listing gain. The company plans to use the raised funds to establish new manufacturing facilities for nutraceutical and veterinary products. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Business Overview and Fund Utilisation The Rs 55.63 crore initial public offering (IPO) of Influx Healthtech was subscribed 41.07 times by 11:26 a.m. on the final day of bidding, Friday, driven by strong interest from retail and non-institutional retail investor portion was subscribed 53.88 times, while the non-institutional investor (NII) segment saw 63.64 times subscription. The qualified institutional buyer (QIB) portion was subscribed 1.71 the grey market, Influx Healthtech shares were commanding a premium of Rs 37–38, indicating an estimated listing price of around Rs 134. This reflects a 39% gain over the issue's upper price band of Rs 96 per IPO opened on June 17 and closes today. It is priced in the range of Rs 91–96 per share, with a minimum lot size of 1,200 Influx Healthtech is a contract development and manufacturing organisation (CDMO) that offers third-party manufacturing and product development services across nutraceuticals, cosmetics, ayurvedic products, and veterinary feed manufacturing operations are based in Thane, where it produces a wide range of products including tablets, gummies, jellies, skincare solutions, and ayurvedic the Rs 55.63 crore raised, Rs 45.07 crore is through a fresh issue and Rs 10.56 crore via offer-for-sale. The company plans to utilise Rs 34.19 crore for establishing two new manufacturing facilities focused on nutraceutical and veterinary products, along with investments in machinery and general corporate FY25, Influx Healthtech reported revenue of Rs 104.99 crore and a net profit of Rs 13.37 shares are proposed to be listed on the NSE SME platform, with a tentative listing date of June 25.: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
15 hours ago
- Business
- Time of India
From rural Telangana to cutting-edge pharma labs: Skilling push lands 78 students jobs, internships in life sciences sector
A Telangana government initiative has transformed the lives of 140 chemistry students, primarily women from disadvantaged backgrounds. Through industry-curated skilling, they secured jobs and internships in pharma companies, with salaries up to ₹3.5 lakh annually. HYDERABAD: For 25-year-old Peddagolla Madhavi from Bilalpur village near Zaheerabad, landing a ₹3.5 lakh per annum job at a Hyderabadbased pharma company was a life-changing moment. Coming from a family dependent on welfare after her father's abandonment and her mother's disability, this chance to work in a contract development and manufacturing organisation (CDMO) was a dream come true. Similarly, 22-year-old Vanjari Gayathri from Sangareddy district secured a position as a research and development trainee at the same company, Sai Life Sciences. Having lost her father a decade ago, Gayathri dreamed of becoming a scientist working on drug development. Birru Ramya, 25, from Kesamudram in Mahabubabad district, secured a paid internship at Aragen Lifesciences, which offers a monthly stipend of ₹15,000 and potential permanent placement at ₹2.5 LPA after four months. These women are among 140 chemistry students that made the cut from over 1,500 applicants of 40 colleges in Telangana for an industrycurated skilling pilot programme rolled out by Telangana govt late last year through the Centre for Fourth Industrial Revolution (C4IR), a thematic healthcare and life sciences centre set up by the World Economic Forum (WEF) in collaboration with Telangana govt. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với sàn môi giới tin cậy IC Markets Tìm hiểu thêm Undo 'The best part was doing lab experiments at University of Hyderabad (UoH) and getting to visit labs of companies. Now I'm looking for accommodation as I have to join by the end of this month," said a thrilled Gayathri in fluent English, describing the practical training that helped her bridge theoretical knowledge garnered in college with hands-on industry experience and soft skills gained from the programme. The students were put through 64 hours of technical training, 40 hours of soft skills training, and eight days of intensive lab training at UoH. Industry experts from various companies and academic institutions too participated in the curriculum designing and training. Immense potential: Min 'Telangana's youth have immense potential. With a curriculum shaped in close collaboration with industry to reflect real-world needs and a targeted, market-aligned training programme, we were able to transform them into globally competitive professionals by prioritising high-demand skill areas and soft skills training,' said IT and industries Minister D Sridhar Babu, who mooted the idea in November 2024. This pilot is just the beginning of the govt's vision to skill 50,000 youth for the life sciences sector over the next five years and position the state as India's most future-ready workforce hub, he added. Though 108 candidates eventually completed the programme, 78 participated in placements and all bagged placements or paid internships, with some even getting multiple offers, said Shakthi Nagappan, director — life sciences and pharma, Telangana. Nagappan said the pilot's success has now encouraged them to focus more aggressively on smaller towns towns to create more opportunities for rural students in Telangana's pharma sector.
Time of India
a day ago
- Business
- Time of India
Telangana govt's skilling programme gives smalltown students a booster shot at pharma careers
Hyderabad: For 25-year-old Peddagolla Madhavi from Bilalpur village near Zaheerabad, landing a Rs 3.5 lakh per annum job at a Hyderabad-based pharma company was a life-changing moment. Coming from a family dependent on welfare after her father's abandonment and her mother's disability, this opportunity to work in a contract development and manufacturing organisation (CDMO) was a dream come true. Similarly, 22-year-old Vanjari Gayathri from Sangareddy district secured a position as a research and development trainee at the same company, Sai Life Sciences. Having lost her father a decade ago, Gayathri always dreamed of becoming a scientist working on drug development. Birru Ramya, 25, from Kesamudram in Mahabubabad district, secured a paid internship at Aragen Lifesciences, which offers a monthly stipend of Rs 15,000 and potential permanent placement at Rs 2.5 LPA after four months. These women are among 140 chemistry students that made the cut from over 1,500 applicants of 40 colleges in Telangana for an industry-curated skilling pilot programme rolled out by Telangana govt late last year through the Centre for Fourth Industrial Revolution (C4IR), a thematic healthcare and life sciences centre set up by the World Economic Forum (WEF) in collaboration with Telangana govt. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo 'The best part was doing lab experiments at University of Hyderabad (UoH) and getting to visit labs of companies. Now I'm looking for accommodation as I have to join by the end of this month," said a thrilled Gayathri in fluent English, describing the practical training that helped her bridge theoretical knowledge garnered in college with hands-on industry experience and soft skills gained from the programme. The students were put through 64 hours of technical training, 40 hours of soft skills training, and eight days of intensive lab training at UoH. Industry experts from various companies and academic institutions too participated in the curriculum designing and training. "Telangana's youth have immense potential. With a curriculum shaped in close collaboration with industry to reflect real-world needs and a targeted, market-aligned training programme, we were able to transform them into globally competitive professionals by prioritising high-demand skill areas and soft skills training,' said Telangana IT and industries Minister D Sridhar Babu, who mooted the idea in November 2024. This pilot is just the beginning of the govt's vision to skill 50,000 youth for the life sciences sector over the next five years and position the state as India's most future-ready workforce hub, he added. Though 108 candidates eventually completed the programme, 78 participated in placements and all bagged placements or paid internships, with some even getting multiple offers, said Shakthi Nagappan, director — life sciences and pharma, Telangana. Nagappan said the pilot's success has now encouraged them to focus more aggressively on smaller towns towns to create more opportunities for rural students in Telangana's pharma sector. Plans are afoot to roll out programmes in biotech, bioinformatics, biostatistics as well as AI and ML and scale up the programme to target over 2,000 students in 2025-36. 'We are talking to global institutions like Dublin-based National Institute for Bioprocessing Research and Training (NIBRT) to curate programmes that can help skill youth for jobs in global capability centres (GCCs),' he added.
Yahoo
a day ago
- Business
- Yahoo
Frost & Sullivan Released Report: "2025 China Pharmaceutical CDMO Industry Insight Blue Book"
Shanghai, China--(Newsfile Corp. - June 19, 2025) - Frost & Sullivan released the "2025 China Pharmaceutical CDMO Industry Insight Blue Book", a comprehensive analysis of the evolution and strategic trajectory of China's pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector. Rooted in an in-depth examination of market dynamics, technological innovation, and global competitiveness, the report elucidates how China's CDMO industry is reshaping the global pharmaceutical value chain through specialized services, operational agility, and cutting-edge capabilities. (To read the Blue Book, go here: "2025 China Pharmaceutical CDMO Industry Insight Blue Book " highlights the following: The Core Position of the CDMO Sector: How CDMOs support pharmaceutical companies across the entire drug development and manufacturing value chain. Four Development Stages of China's CDMO Industry: From Policy Liberalization to Global Competition, tracing the evolution and growth of China's CDMO sector. Dual-Engine Phase of Scale Expansion and Domain Segmentation: The expansion and specialization trends within China's CDMO industry. Sub-sectors of CDMO: Detailed insights into Small Molecule, Peptide, Antibody, ADC, and CGT CDMO segments. Multi-Point Growth Pattern: The diverse growth points and strategic developments of China's CDMO industry. Introduction to Selected Chinese CDMOs: Showcasing leading CDMOs in China and their contributions to the industry, including BiBo Pharma, Healthnice, Porton Pharma, ChemExpress, OBiO Technology, Pharmaron, PharmaBlock, Yaohai Bio-Pharma, uBriGene, Intellective Bio, Chinese Peptide, and TOT Biopharm. The CDMO Sector Holds a Core Position in the Pharmaceutical Industry As a major part of the outsourcing pharmaceutical service industry, CDMOs support pharmaceutical companies across the entire chain, from drug discovery to market launch, and from process development to large-scale manufacturing. They rely on large-scale production capacity and high value-added R&D and manufacturing processes. As a result, CDMOs have become key partners and hold a core position in China's pharmaceutical industry. Demand Drives Expansion and Subdivision of CDMOs The continued evolution of global demand for biopharmaceutical R&D and manufacturing is pushing China's CDMO industry into a dual-engine phase of scale expansion and domain segmentation. On one hand, the increasing technical complexity of emerging areas such as CGT, ADCs, and nucleic acid drugs is driving strong demand for specialized CDMO services. On the other hand, traditional segments like small molecule drugs continue to expand production capacity due to process optimization and steady market demand. At the same time, differentiated demands from pharmaceutical companies are accelerating the diversification of service models. Biopharma companies tend to divest non-core manufacturing functions to focus on innovative pipelines, thereby driving CDMOs toward high-end process development. Biotech firms, constrained by resources, increasingly rely on one-stop services that provide full-cycle support from target validation to IND filing, prompting the rise of full-chain CDMO platforms. In response, Chinese CDMOs are using technological deployment and service model innovation to build entry barriers in niche areas while using large-scale production capacity to capture global orders, thus establishing a dual-path development model of "high-end breakthroughs + foundational consolidation."。 Four Development Stages : Policy, Technology, and Capital-Driven the Closed-Loop Growth of China's CDMO Industry China's pharmaceutical CDMO industry has gone through four key stages: policy liberalization, technology transfer, capital-driven growth, and global competition. The sector has moved from the early phase of reliant on foreign technology and policy incentives to a more advanced stage defined by deep technical expertise, global production layout, and integrated ecosystems. On the policy side, the implementation of the MAH system, stricter GMP standards, and medical insurance reform have pushed pharmaceutical companies to separate their manufacturing functions, creating strong demand for CDMO services. On the technology side, advancements in continuous flow chemistry, enzymatic catalysis, and AI-based drug design have increased the added value of services. On the capital side, funding has fueled the rise of emerging fields. The industry now follows a closed-loop development model: policy-driven demand-technology-driven service upgrades-capital-driven expansion-global ecosystem integration. This reflects a shift in China's CDMO sector from rapid scale expansion to high-quality development. A Multi-Front Development Trend of China's CDMO Industry Chinese CDMO enterprises are strategically advancing vertically integrated service capabilities across the pharmaceutical value chain through organic growth and strategic mergers, aligning with China's push for high-quality industrial development. As sector competition intensifies, differentiation through niche specialization has become critical. To address global capacity imbalances and optimize biologics production economics, CDMOs are prioritizing operational efficiency upgrades and smart manufacturing adoption. Leading players are simultaneously executing multi-pronged globalization strategies: establishing GMP-compliant facilities in key overseas markets to secure long-term international competitiveness, while deepening technological moats through specialized R&D investments in advanced modalities. This dual approach enables breakthroughs in traditional competitive frameworks through differentiated capabilities. Global capacity networks are being rapidly expanded in overseas production hubs and acquisitions of internationally certified manufacturers, forming interconnected supply chains aligned with global pharmaceutical collaboration systems. Simultaneously, innovative CRDMO models are integrating value chain resources to create end-to-end service ecosystems spanning drug discovery to commercial manufacturing. Case studies including BiBo Pharma, Porton Pharma, Healthnice, ChemExpress, OBiO Technology, Pharmaron, PharmaBlock, Yaohai Bio-Pharma, uBriGene, Intellective Bio and Chinese Peptide exemplify the diversified growth trajectories shaping China's CDMO landscape. These enterprises demonstrate how strategic focus on technological innovation, operational excellence, and global integration is redefining the sector's competitive dynamics. About Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 60 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Media ContactContact: Qian LiCompany Name: Frost & SullivanWebsite: To view the source version of this press release, please visit
